. Global and . Burden-of-parkinson's-disease, a systematic analysis for the Global Burden of Disease Study 2016. GBD 2016 Parkinson's Disease Collaborators, Lancet Neurol, vol.17, issue.18, pp.30295-30298, 1990.

P. Martinez-martin, C. Rodriguez-blazquez, M. M. Kurtis, and K. R. Chaudhuri, NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease, Mov Disord, vol.26, pp.399-406, 2011.

S. E. Soh, M. E. Morris, and J. L. Mcginley, Determinants of health-related quality of life in Parkinson's disease: A systematic review, Parkinsonism Relat Disord, vol.17, pp.1-9, 2011.

P. Martinez-martin, C. Rodriguez-blazquez, and M. J. Forjaz, Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients, Eur J Neurol, vol.21, pp.519-524, 2014.

R. Balestrino and P. Martinez-martin, Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease, J Neurol Sci, vol.373, pp.173-178, 2017.

X. J. Tu, W. J. Hwang, H. I. Ma, L. H. Chang, and S. P. Hsu, Determinants of generic and specific health-related quality of life in patients with Parkinson's disease, PLoS One, vol.12, p.178896, 2017.

P. Martinez-martin, An introduction to the concept of "quality of life in Parkinson's disease, J Neurol, vol.245, issue.1, pp.2-6, 1998.

R. Berzon, R. D. Hays, and S. A. Shumaker, International use, application and performance of health-related quality of life instruments, Qual Life Res, vol.2, pp.367-368, 1993.

R. Fitzpatrick, A. Masson, and S. A. , Quality of life in health care: Concepts and components, pp.1-15, 1999.

, Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products, European Medicines Agency, 2005.

D. Food and . Administration, Guidance for Industry Patient-Reported Outcome Measures: Use in medical product development to support labeling claims. U.S. Department of Health and Human Services Food and Drug Administration, 2009.

P. Martinez-martin, M. Jeukens-visser, and K. E. Lyons, Health-related quality-of-life scales in Parkinson's disease: critique and recommendations, Mov Disord, vol.26, pp.2371-2380, 2011.

G. Deuschl, M. Schüpbach, and K. Knudsen, Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study, Parkinsonism Relat Disord, vol.19, pp.56-61, 2013.

W. M. Schuepbach, J. Rau, and K. Knudsen, Neurostimulation for Parkinson's disease with early motor complications, N Engl J Med, vol.368, pp.610-622, 2013.

G. Deuschl, C. Schade-brittinger, Y. Agid, and . Group, Neurostimulation for Parkinson's disease with early motor complications, N Engl J Med, vol.368, p.2038, 2013.

E. Lhommé-e, L. Wojtecki, and V. Czernecki, Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EAR-LYSTIM trial): secondary analysis of an open-label randomised trial, Lancet Neurol, vol.17, pp.223-231, 2018.

W. Schuepbach, L. Tonder, and A. Schnitzler, Quality of life predicts outcome of deep brain stimulation in early Parkinson disease, Neurology, vol.92, issue.10, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02373051

T. A. Mestre, A. J. Espay, C. Marras, M. H. Eckman, P. Pollak et al., Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease: the EARLYSTIM trial: early is not always better, Mov Disord, vol.29, pp.1751-1756, 2014.

M. Sperens, K. Hamberg, and G. M. Hariz, Are Patients Ready for "EARLYSTIM"? Attitudes towards Deep Brain Stimulation among Female and Male Patients with Moderately Advanced Parkinson's Disease, Parkinsons Dis, 2017.

L. Y. Cabrera, J. Goudreau, and C. Sidiropoulos, Critical appraisal of the recent US FDA approval for earlier DBS intervention, Neurology, vol.91, pp.133-136, 2018.

M. T. King, A point of minimal important difference (MID): a critique of terminology and methods, Expert Rev Pharmacoecon Outc Res, vol.11, pp.171-184, 2011.

D. Fischer, A. L. Stewart, D. A. Bloch, K. Lorig, D. Laurent et al., Capturing the patient's view of change as a clinical outcome measure, JAMA, vol.282, issue.12, pp.1157-62, 1999.

T. Forkmann, A. Scherer, M. Boecker, M. Pawelzik, R. Jostes et al., The Clinical Global Impression Scale and the influence of patient or staff perspective on outcome, BMC Psychiatry, vol.11, p.83, 2011.

R. Jaeschke, J. Singer, and G. H. Guyatt, Measurement of health status. Ascertaining the minimal clinically important difference, Contr Clin Trials, vol.10, pp.407-415, 1989.

R. D. Crosby, R. L. Kolotkin, and G. R. Williams, Defining clinically meaningful change in health-related quality of life, J Clin Epidemiol, vol.56, pp.44-45, 2003.

K. W. Wyrwich, J. M. Norquist, W. R. Lenderking, and S. Acaster, Methods for interpreting change over time in patientreported outcome measures, Industry Advisory Committee of International Society for Quality of Life Research (ISOQOL), vol.22, pp.475-483, 2013.

G. R. Norman, J. A. Sloan, and K. W. Wyrwich, Interpretation of changes in health-related quality of life: the remarkable universality of a half a standard deviation, Med Care, vol.41, pp.582-592, 2003.

J. A. Sloan, D. Cella, R. D. Hays, and R. , Clinical significance of patient-reported questionnaire data: another step toward consensus, J Clin Epidemiol, vol.58, pp.1217-1219, 2005.

A. Bowling, Research Methods in Health: Investigating Health and Health Services Research, p.202, 2002.

D. Revicki, R. D. Hays, D. Cella, and J. Sloan, Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes, J Clin Epidemiol, vol.61, pp.102-109, 2008.

G. R. Norman, F. G. Sridhar, G. H. Guyatt, and S. D. Walter, Relation of distribution-and anchor-based approaches in interpretation of changes in health-related quality of life, Med Care, vol.39, pp.1039-1086, 2001.

K. W. Wyrwich, M. Bullinger, and N. Aaronson, Estimating clinically significant differences in quality of life outcomes, Qual Life Res, vol.14, pp.285-295, 2005.

H. C. De-vet, C. B. Terwee, R. W. Ostelo, H. Beckerman, D. L. Knol et al., Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change, Health Qual Life Outcomes, vol.4, p.54, 2006.

D. Turner, H. J. Schü-nemann, L. E. Griffith, D. E. Beaton, A. M. Griffiths et al., The minimal detectable change cannot reliably replace the minimal important difference, J Clin Epidemiol, vol.63, issue.1, pp.28-36, 2010.

P. Martinez-martin and M. M. Kurtis, Health-related quality of life as an outcome variable in Parkinson's disease, Ther Adv Neurol Disord, vol.5, issue.2, pp.105-122, 2012.

V. Peto, C. Jenkinson, and R. Fitzpatrick, Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire, Age Ageing, vol.30, issue.4, pp.299-302, 2001.

H. C. De-vet, C. B. Terwee, D. L. Knol, and L. M. Bouter, When to use agreement versus reliability measures, J Clin Epidemiol, vol.59, issue.10, pp.1033-1042, 2006.

P. Martínez-martin, F. J. Carod-artal, L. Da-silveira-ribeiro, S. Ziomkowski, A. P. Vargas et al., Longitudinal psychometric attributes, responsiveness, and importance of change: An approach using the SCOPA-Psychosocial questionnaire, Mov Disord, vol.23, issue.11, pp.1516-1539, 2008.

K. Horváth, Z. Aschermann, M. Ková-cs, A. Makkos, M. Harmat et al., Changes in quality of life in Parkinson's disease: How large must they be to be relevant?, Neuroepidemiology, vol.48, issue.1-2, pp.1-8, 2017.

S. K. Holden, C. E. Koljack, L. P. Prizer, S. H. Sillau, J. M. Miyasaki et al., Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison, Parkinsonism Relat Disord, vol.65, pp.172-177, 2019.

P. Reddy, P. Martinez-martin, R. G. Brown, K. R. Chaudhuri, J. P. Lin et al., Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD). Health Qual Life Outcomes, vol.12, p.11, 2014.

P. Martinez-martin and G. Deuschl, Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease, Mov Disord, vol.22, issue.6, pp.757-65, 2007.

P. Martinez-martin, Cuánto ha mejorado la calidad de vida de los pacientes con enfermedad de Parkinson?, Rev Esp Trast Mov, vol.6, pp.14-21, 2014.

P. Martinez-martin, C. Rodriguez-blazquez, M. J. Forjaz, and M. M. Kurtis, Impact of pharmacotherapy on quality of life in patients with Parkinson's disease, CNS Drugs, vol.29, issue.5, p.25968563, 2015.

G. Kleiner-fisman, J. Herzog, D. N. Fisman, F. Tamma, K. E. Lyons et al., Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes, Mov Disord, vol.21, pp.290-304, 2006.

A. M. Damiano, C. Snyder, B. Strausser, and M. K. Willian, A review of health-related quality-of-life concepts and measures for Parkinson's disease, Qual Life Res, vol.8, issue.3, pp.235-278

A. Schrag, M. Jahanshahi, and N. Quinn, What contributes to quality of life in patients with Parkinson's disease?, J Neurol Neurosurg Psychiatry, vol.69, issue.3, pp.308-320, 2000.

F. J. Carod-artal, A. P. Vargas, and P. Martinez-martin, Determinants of quality of life in Brazilian patients with Parkinson's disease, Mov Disord, vol.22, issue.10, pp.1408-1423, 2007.

S. E. Soh, J. L. Mcginley, J. J. Watts, R. Iansek, A. T. Murphy et al., Determinants of health-related quality of life in people with Parkinson's disease: a path analysis, Qual Life Res, vol.22, issue.7, p.23070750, 2013.

Y. Wu, X. Y. Guo, Q. Q. Wei, W. Song, K. Chen et al., Determinants of the quality of life in Parkinson's disease: results of a cohort study from Southwest China, J Neurol Sci, vol.15, issue.1-2, pp.144-153, 2014.